2019 ISCD Official PositionBone Densitometry in Transgender and Gender Non-Conforming (TGNC) Individuals: 2019 ISCD Official Position
Introduction
Transgender/gender nonconforming (TGNC) individuals experience many changes that have the potential to affect their bone mineral density (BMD). This fact raises the question of whether TGNC individuals should have routine densitometry at a younger age than cisgender patients, and whether a transgender woman or man should have the Z-score calculated according to a male or female reference database. The ISCD charged this Task Force with addressing the following questions regarding bone densitometry in the TGNC population:
- 1.
What are the indications for performing a baseline dual-energy X-ray absorptiometry (DXA) in TGNC individuals?
- 2.
In which TGNC individuals should DXA measurements be repeated, and at what interval?
- 3.
Which databases can be used for diagnosis?
- 4.
What parameters need to be included in the DXA report for TGNC individuals?
Before these questions are addressed in turn, some comments about terminology relevant to TGNC individuals are in order. An attempt was made to use terms surrounding the management of TGNC individuals that are clear, consistent with current scientific usage, and acceptable to TGNC individuals (1). This manuscript was vetted with experts in the management of TGNC individuals and with representatives of the TGNC community. Please understand that no agenda motivated the members of the Task Force other than to support the most compassionate and scientifically valid care for TGNC individuals.
The following is a brief glossary of the terms used in this manuscript:
- 1.
TGNC: this refers to individuals whose gender identity does not correspond to the recorded sex at birth. The gender identity may fall within the typical gender binary of male or female, or may not conform to the gender binary.
- 2.
Transgender man: an individual who was recorded female at birth, who has a masculine gender identity.
- 3.
Transgender woman: an individual who was recorded male at birth, who has a feminine gender identity.
- 4.
Cisgender: a patient whose gender identity conforms with the sex recorded at birth.
- 5.
Gender-affirming hormone treatment: for transgender women, this includes GnRH analogs or androgen blockers, and estrogen. For transgender men, this includes testosterone.
- 6.
Gender nonbinary individuals: individuals who do not experience gender identity in a binary fashion, as a man or a woman. This term encompasses a concept similar to “gender non-conforming.”
- 7.
Male Z-score: a Z-score that is calculated by comparing the BMD of the individual to the mean of age- and ethnicity-matched men.
- 8.
Female Z-score: a Z-score that is calculated by comparing the BMD of the individual to the mean of age- and ethnicity-matched women.
Section snippets
Methodology and Data Sources
To determine whether TGNC individuals have a BMD different from that of cisgender individuals, and to determine the effect of gender-affirming hormonal treatment on bone metabolism and bone density status in TGNC individuals, a search of the literature using Medline, Pubmed, and Google Scholar was done in November 2018. The search terms that were used were “transgender” and “bone,” “transsexual” and “bone,” and “gender dysphoria” and “bone.” The reference lists of these articles were also
Position 1
Baseline BMD testing is indicated for TGNC individuals if they have any of the following conditions:
- a.
History of gonadectomy or therapy that lowers endogenous gonadal steroid levels prior to initiation of hormone therapy.
- b.
Hypogonadism with no plan to take gender-affirming hormone therapy.
- c.
Existing ISCD indications for BMD testing, such as glucocorticoid use and hyperparathyroidism, apply.
Grade for transgender men and women: Good, A, W.
Grade for gender nonconforming individuals: Poor, C, W.
Discussion/Summary
TGNC individuals experience profound changes that can affect many aspects of their health. Because BMD is dependent on hormones and other factors, it is widely thought that TGNC individuals start off with BMD typical for the sex recorded at birth and that the BMD gradually becomes more similar to that of the gender corresponding with gender identity with gender-affirming hormone treatment. The literature supports the opposite view; there are abundant data to suggest that transgender women start
Acknowledgments
We thank William Leslie and Tom Kelly for the data showing the difference in Z-score when calculated according to male vs female reference data for GE-Lunar and Hologic, respectively. We thank Amy Sholiton for assistance with editing.
References (35)
- et al.
Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy
Bone
(2013) - et al.
Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents
Bone
(2017) - et al.
Prevalence of low bone mass in relation to estrogen treatment and body composition in male-to-female transsexual persons
J Clin Densitom
(2009) - et al.
Body composition, volumetric and areal bone parameters in male-to-female transsexual persons
Bone
(2008) - et al.
Cross‐sex hormone therapy in trans persons is safe and effective at short‐time follow‐up: results from the European Network for the investigation of gender incongruence
J Sex Med
(2014) - et al.
Bone mass, bone turnover, vitamin D, and estrogen receptor gene polymorphisms in male to female transsexuals—effects of estrogenic treatment on bone metabolism of the male
J Clin Densitom
(2003) - et al.
Cross-sex pattern of bone mineral density in early onset gender identity disorder
Horm Behav
(2007) - et al.
Effects of hormone deficiency, androgen therapy and calcium supplementation on bone mineral density in female transsexuals
Maturitas
(1997) - et al.
Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals
J Sex Med
(2008) - et al.
Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals
J Sex Med
(2010)
Effects of three different testosterone formulations in female-to-male transsexual persons
J Sex Med
2013 International Society for Clinical Densitometry position development conference: task force on normative databases
J Clin Densitom
Persons of nonbinary gender—awareness, visibility, and health disparities
N Engl J Med
Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study
Osteoporos Int
Impact of cross-sex hormone therapy on bone mineral density and body composition in transwomen
Clin Endocrinol (Oxf)
Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria
J Clin Endocrinol Metab
Bone in trans persons
Curr Opin Endocrinol Diabetes Obes
Cited by (39)
Positions of The International Society for Clinical Densitometry and Their Etiology: A Scoping Review
2023, Journal of Clinical DensitometryInterpretation of Bone Mineral Density Z-Scores by Dual-Energy X-Ray Absorptiometry in Transgender and Gender Diverse Youth Prior to Gender-Affirming Medical Therapy
2022, Journal of Clinical DensitometryCitation Excerpt :To date, all published studies describing BMD data by DXA in TGD youth have reported findings using BMD Z-scores of chronologic age and sex designated at birth reference standards (3–7). The International Society of Clinical Densitometry (ISCD) provided its first guidance on interpretation of BMD by DXA in TGD individuals in the 2019 adult position statement; namely, that BMD Z-scores should be interpreted using the reference standards corresponding to the gender identity if there is a binary gender identity, and to the sex designated at birth if there is a non-binary gender identity (8,9). However, there is no specific guidance for DXA interpretation of TGD youth included in the 2019 ISCD pediatric position statement.
DXA Scan Variants in Transgender Patients
2022, Journal of Clinical DensitometryCitation Excerpt :The qualitative data was recorded and DXA scan procedures were determined as "correct" or "incorrect" based on guidance from the International Society of Clinical Densitometry. According to the ISCD Adult Official Positions updated as of May 28th, 2019, TGNC individuals needing DXA scans should follow rules depicted in Fig. 1 (1). Results were then translated into a quantitative total score: 1 point given for each correct T- score or Z-score and 0 given for each incorrect T-score or Z-score.
Bone density and bone marrow composition in transgender girls prior to pubertal blockade: A case series
2022, BoneCitation Excerpt :Anthropometric measurements were obtained. Axial areal BMD measurements of the total body less head and lumbar spine (L1–4) were obtained by DXA (Hologic, Inc., Bedford, MA) and Z-scores for chronological age were calculated according to male standards (i.e., assigned sex at birth) [9]. BMD Z-scores were not height-adjusted as no participants had a height Z-score ≤ −1.0.
Hormone Concentrations in Transgender Women Who Self-Prescribe Gender Affirming Hormone Therapy: A Retrospective Study
2022, Journal of Sexual MedicineCitation Excerpt :Only 23% of transwomen who completed gonadectomy and received consultation by a surgeon were able to achieve an optimal estradiol concentration. Having inadequate estradiol levels, after gonadectomy could impair their overall health, especially long-term skeletal health.15,16 Our data suggest that transgender women who underwent gonadectomy did not have proper GAHT counseling.